Target intelligence / Profile preview

Integrin alpha-E (ITGAE)

Target
ITGAE
Molecular classification
Receptor, Integrin
01

Overview

Integrin alpha-E (also known as CD103 or ITGAE) is a transmembrane glycoprotein that non-covalently pairs with the integrin beta-7 subunit to form the heterodimeric integrin alpha-E/beta-7. This integrin is predominantly expressed on intraepithelial lymphocytes (IELs), mucosal T cells, and subsets of dendritic cells. Its primary ligand is E-cadherin, an adhesion molecule constitutively expressed on epithelial cells. The interaction between integrin alpha-E/beta-7 and E-cadherin is crucial for the homing, retention, and positioning of lymphocytes within mucosal and epithelial tissues, such as the gut, skin, and lungs.

In disease states, integrin alpha-E plays a dual role. In inflammatory bowel diseases (IBD) like ulcerative colitis and Crohn's disease, it mediates the retention of pathogenic, pro-inflammatory T cells that drive chronic mucosal inflammation. Conversely, in oncology, CD103 is a key marker for tumor-infiltrating lymphocytes (TILs), where its expression correlates with tumor-reactive cytotoxic T cell activity and favorable prognosis. Therapeutic strategies targeting this pathway include monoclonal antibodies like etrolizumab and ABBV-243, which block the beta-7 subunit to disrupt both alpha-E/beta-7 and alpha-4/beta-7 interactions, thereby reducing lymphocyte retention and trafficking in the gut. Additionally, CD103-targeted antibody-drug conjugates (ADCs) and imaging tracers are being explored to selectively deplete pathogenic cells or monitor immune responses in cancer.

Other names
CD103ITGAEIntegrin alpha-IELHML-1 antigenMucosal lymphocyte 1 antigenIntegrin subunit alpha E
02

Mechanism of action

Inhibition of integrin-mediated cell adhesion and signaling by blocking the interaction between the integrin alpha-E/beta-7 heterodimer and its ligand E-cadherin, thereby preventing the retention and activation of pro-inflammatory lymphocytes in mucosal tissues.

03

Biological functions

Cell adhesionImmune responseLymphocyte retentionTissue-specific homingSignal transduction
04

Disease associations

InflammationCancerAutoimmune diseaseInflammatory bowel disease
05

Safety considerations

Impaired mucosal immunityIncreased risk of infections (e.g., gastrointestinal or respiratory infections)Potential for systemic immunosuppressionBystander tissue damage if using depleting agents (e.g., antibody-drug conjugates)
06

Interacting drugs

1 more in the full profile.

07

Biomarkers

ITGAE gene expressionCD103 expression on tumor-infiltrating lymphocytes (TILs)CD103 expression on regulatory T cells (Tregs)CD103 expression in hairy cell leukemia

Beyond the preview

Go deeper on Integrin alpha-E (ITGAE).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Integrin alpha-E (ITGAE).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call